1. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971.
2. Shibata K, Suzuki A, Watanabe T, Takasu N, Hirai L, Kimura W.ZEP-1 and E-cadherin expression may predict recurrence –free survival in patient with invasive ductal breast carcinoma. Yamagata Med J. 2015;33(2):61-69. doi: 10.15022\00003468.
3. Benzina S, Beauregard AP, Guerrette R, Jean S, Faye MD, Laflamme M, et al. Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes. Oncotarget. 2017;8(7):12052-12066. doi: 10.18632/oncotarget.14511.
4. Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4:6. doi:10.1186/s40169-015-0048-3.
5. Hegazy A. Clinical embryology for medical students and postgraduate doctors. Berlin: LAP ‘Lambert Academic Publishing’; 2014.
6. Huang X, Zhang C, Cai J, Shi G, Ke A, Dong Z, et al. Comprehensive multiple molecular profile of epithelial mesenchymal transition in intrahepatic cholangiocarcinoma patients. PLoS One. 2014; 9(5): e96860.
7. Chen J, Wang T, Zhou YC, Gao F, Zhang ZH, Xu H, et al. Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer.J Exp Clin Cancer Res. 2014;33:38. doi: 10.1186/1756-9966-33-38.
8. Kang S, Chae YS, Lee SJ, Kang BW, Kim JG, Kim WW, et al. Aquaporin 3 Expression predicts survival in patients with HER2-positive early breast cancer. Anticancer Res. 2015;35(5):2775-82.
9. Marlar S, Jensen HH, Login FH, Nejsum LN. Aquaporin-3 in Cancer. Int J Mol Sci. 2017;18(10). pii: E2106. doi: 10.3390/ijms18102106.
10. Maitham AK, Luqmani YA.Role of aquaporins in breast cancer progression and metastasis. Chapter 4: Aquaporin-3 in cancer. 2016.p.59-83. Available at: http://dx.doi.org/10.5772/64446.
11. Chen R, Shi Y, Amiduo R, Tuokan T, Suzuk L.Expression and prognostic value of aquaporin 1, 3 in cervical carcinoma in women of Uygur ethnicity from Xinjiang, China. PLoS One. 2014;9(6): e98576. doi:10.1371/journal. pone.0098576.
12. Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, et al. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol. 2008;62(5):857-65. doi: 10.1007/s00280-007-0674-6.
13. Hemalatha A, Suresh TN, Harendra Kumar ML. Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parameters. Indian J Cancer. 2013;50:189-94
14. Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, et al. Androgen receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients. PLoS One. 2015;10(6):e0128368.
15. Abdelrahman AE, Arafa SA, Ahmed RA. Prognostic Value of twist-1, E-cadherin and EZH2 in prostate cancer: An immunohistochemical study. Turk Patoloji Derg. 2017;33(3):198-210 doi: 10.5146/tjpath.2016.01392.
16. Ashaie MA, Chowdhury EH.Cadherins: the superfamily critically involved in breast cancer. Curr Pharm Des. 2016; 22:616-38
17. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ.WHO classification of tumors of the breast. 4th ed. Lyon, France: IARC Press; 2012.
18. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual, 7th ed. New York: Springer; 2010.
19. Huang YT, Zhou J, Shi S, Xu HY, Qu F, Zhang D, et al. Identification of estrogen response element in aquaporin-3 gene that mediates estrogen-induced cell migration and invasion in estrogen receptor-positive breast cancer. Sci Rep. 2015; 5:12484. doi: 10.1038/srep12484.
20. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21 Suppl 7:vii89-92. doi: 10.1093/annonc/mdq292.
21. Jeong H, Ryu YJ, An J, Lee Y, Kim A. Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology. 2012;60(6B):E87-95. doi:10.1111/j.1365-2559.2012.04195.x.
22. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006; 12: 1533–1539.
23. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68(4):989-97. doi:10.1158/0008-5472.CAN-07-2017.
24. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010;24(6):1838-51. doi: 10.1096/fj.09-151639.
25. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515-27.
26. Hendrix MJ, Seftor EA, Seftor RE, Trevor KT. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol. 1997;150(2):483-95.
27. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30(12):1436-48. doi: 10.1038/onc.2010.509.
28. Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-Vuorinen A, Soini Y. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res Treat. 2013;138(1):81-90. doi: 10.1007/s10549-013-2442-0.
29. Calaf G, Balajee AS, Montalvo-villagra MT, leon M, Navarrete MD, González alvarez R, et al. Vimentin and Notch as biomarkers for breast cancer progression. Oncol Lett. 2014; 7(3): 721-7. doi: 10.3892/ol.2014.1781.
30. Yamashita N, Tokunaga E, Kitao H, Hisamats Y, Taketani K, Akiyoshi S, et al. Vimentin as a poor prognostic factor for triple-negative breast cancer. Cancer Res Clin Oncol. 2013;139:739-46. doi 10.1007/s00432-013-1376-6.
31. Shibata K, Suzuki A, Watanabe T, Takasu N, Hirai I, Kimura W. ZEB-1 and E-cadherin expression may predict recurrence-free survival in patients with invasive ductal breast carcinoma. Yamagata Med J. 2015;33(2):61-9.
32. LiZ, Yin S, Liu W, Zhang L, Chen B. Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis. Oncotarget. 2017; 8:10, 16445-55.
33. Wang J, Feng L, Zhu Z, Zheng, M, Wang D, Chen Z, et al. Aquaporins as diagnostic and therapeutic targets in cancer: How far we are? J Transl Med. 2015; 96:13-29.
34. Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res. 2013; 32:97. doi:10.1186/1756-9966-32-97.
35. Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, et al. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res. 2013;32:62. doi:10.1186/1756-9966-32-6.
1. Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971.
2. Shibata K, Suzuki A, Watanabe T, Takasu N, Hirai L, Kimura W.ZEP-1 and E-cadherin expression may predict recurrence –free survival in patient with invasive ductal breast carcinoma. Yamagata Med J. 2015;33(2):61-69. doi: 10.15022\00003468.
3. Benzina S, Beauregard AP, Guerrette R, Jean S, Faye MD, Laflamme M, et al. Pax-5 is a potent regulator of E-cadherin and breast cancer malignant processes. Oncotarget. 2017;8(7):12052-12066. doi: 10.18632/oncotarget.14511.
4. Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4:6. doi:10.1186/s40169-015-0048-3.
5. Hegazy A. Clinical embryology for medical students and postgraduate doctors. Berlin: LAP ‘Lambert Academic Publishing’; 2014.
6. Huang X, Zhang C, Cai J, Shi G, Ke A, Dong Z, et al. Comprehensive multiple molecular profile of epithelial mesenchymal transition in intrahepatic cholangiocarcinoma patients. PLoS One. 2014; 9(5): e96860.
7. Chen J, Wang T, Zhou YC, Gao F, Zhang ZH, Xu H, et al. Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer.J Exp Clin Cancer Res. 2014;33:38. doi: 10.1186/1756-9966-33-38.
8. Kang S, Chae YS, Lee SJ, Kang BW, Kim JG, Kim WW, et al. Aquaporin 3 Expression predicts survival in patients with HER2-positive early breast cancer. Anticancer Res. 2015;35(5):2775-82.
9. Marlar S, Jensen HH, Login FH, Nejsum LN. Aquaporin-3 in Cancer. Int J Mol Sci. 2017;18(10). pii: E2106. doi: 10.3390/ijms18102106.
10. Maitham AK, Luqmani YA.Role of aquaporins in breast cancer progression and metastasis. Chapter 4: Aquaporin-3 in cancer. 2016.p.59-83. Available at: http://dx.doi.org/10.5772/64446.
11. Chen R, Shi Y, Amiduo R, Tuokan T, Suzuk L.Expression and prognostic value of aquaporin 1, 3 in cervical carcinoma in women of Uygur ethnicity from Xinjiang, China. PLoS One. 2014;9(6): e98576. doi:10.1371/journal. pone.0098576.
12. Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, et al. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol. 2008;62(5):857-65. doi: 10.1007/s00280-007-0674-6.
13. Hemalatha A, Suresh TN, Harendra Kumar ML. Expression of vimentin in breast carcinoma, its correlation with Ki67 and other histopathological parameters. Indian J Cancer. 2013;50:189-94
14. Ricciardi GR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G, et al. Androgen receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients. PLoS One. 2015;10(6):e0128368.
15. Abdelrahman AE, Arafa SA, Ahmed RA. Prognostic Value of twist-1, E-cadherin and EZH2 in prostate cancer: An immunohistochemical study. Turk Patoloji Derg. 2017;33(3):198-210 doi: 10.5146/tjpath.2016.01392.
16. Ashaie MA, Chowdhury EH.Cadherins: the superfamily critically involved in breast cancer. Curr Pharm Des. 2016; 22:616-38
17. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ.WHO classification of tumors of the breast. 4th ed. Lyon, France: IARC Press; 2012.
18. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual, 7th ed. New York: Springer; 2010.
19. Huang YT, Zhou J, Shi S, Xu HY, Qu F, Zhang D, et al. Identification of estrogen response element in aquaporin-3 gene that mediates estrogen-induced cell migration and invasion in estrogen receptor-positive breast cancer. Sci Rep. 2015; 5:12484. doi: 10.1038/srep12484.
20. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21 Suppl 7:vii89-92. doi: 10.1093/annonc/mdq292.
21. Jeong H, Ryu YJ, An J, Lee Y, Kim A. Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology. 2012;60(6B):E87-95. doi:10.1111/j.1365-2559.2012.04195.x.
22. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, Calero F, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006; 12: 1533–1539.
23. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68(4):989-97. doi:10.1158/0008-5472.CAN-07-2017.
24. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 2010;24(6):1838-51. doi: 10.1096/fj.09-151639.
25. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10(6):515-27.
26. Hendrix MJ, Seftor EA, Seftor RE, Trevor KT. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol. 1997;150(2):483-95.
27. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30(12):1436-48. doi: 10.1038/onc.2010.509.
28. Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-Vuorinen A, Soini Y. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res Treat. 2013;138(1):81-90. doi: 10.1007/s10549-013-2442-0.
29. Calaf G, Balajee AS, Montalvo-villagra MT, leon M, Navarrete MD, González alvarez R, et al. Vimentin and Notch as biomarkers for breast cancer progression. Oncol Lett. 2014; 7(3): 721-7. doi: 10.3892/ol.2014.1781.
30. Yamashita N, Tokunaga E, Kitao H, Hisamats Y, Taketani K, Akiyoshi S, et al. Vimentin as a poor prognostic factor for triple-negative breast cancer. Cancer Res Clin Oncol. 2013;139:739-46. doi 10.1007/s00432-013-1376-6.
31. Shibata K, Suzuki A, Watanabe T, Takasu N, Hirai I, Kimura W. ZEB-1 and E-cadherin expression may predict recurrence-free survival in patients with invasive ductal breast carcinoma. Yamagata Med J. 2015;33(2):61-9.
32. LiZ, Yin S, Liu W, Zhang L, Chen B. Prognostic value of reduced E-cadherin expression in breast cancer: a meta-analysis. Oncotarget. 2017; 8:10, 16445-55.
33. Wang J, Feng L, Zhu Z, Zheng, M, Wang D, Chen Z, et al. Aquaporins as diagnostic and therapeutic targets in cancer: How far we are? J Transl Med. 2015; 96:13-29.
34. Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res. 2013; 32:97. doi:10.1186/1756-9966-32-97.
35. Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, et al. Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res. 2013;32:62. doi:10.1186/1756-9966-32-6.